Clinical Trial Detail

NCT ID NCT03737994
Title Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-Small Cell Lung Cancer (The NCI-NRG ALK Master Protocol)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

lung non-small cell carcinoma

Therapies

Cisplatin + Lorlatinib

Carboplatin + Lorlatinib

Ceritinib

Alectinib + Cisplatin

Alectinib + Carboplatin

Ceritinib + Cisplatin

Pemetrexed Disodium

Carboplatin + Ceritinib

Cisplatin + Ensartinib

Carboplatin + Ensartinib

Brigatinib + Cisplatin

Brigatinib

Alectinib

Brigatinib + Carboplatin

Ensartinib

Cisplatin + Pemetrexed Disodium

Crizotinib

Carboplatin + Pemetrexed Disodium

Lorlatinib

Age Groups: adult senior

Additional content available in CKB BOOST